Currently, there are 17.21M common shares owned by the public and among those 15.68M shares have been available to trade.
The company’s stock has a 5-day price change of -57.11% and -67.01% over the past three months. UBX shares are trading -75.14% year to date (YTD), with the 12-month market performance down to -64.86% lower. It has a 12-month low price of $0.36 and touched a high of $3.10 over the same period. UBX has an average intraday trading volume of 308.40K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -53.17%, -58.15%, and -73.61% respectively.
Institutional ownership of Unity Biotechnology Inc (NASDAQ: UBX) shares accounts for 11.46% of the company’s 17.21M shares outstanding.
It has a market capitalization of $5.91M and a beta (3y monthly) value of 0.93. The earnings-per-share (ttm) stands at -$1.63. Price movements for the stock have been influenced by the stock’s volatility, which stands at 39.23% over the week and 17.00% over the month.
Earnings per share for the fiscal year are expected to increase by 42.86%, and 11.36% over the next financial year. EPS should grow at an annualized rate of 40.77% over the next five years, compared to 39.36% over the past 5-year period.
Looking at the support for the UBX, a number of firms have released research notes about the stock. H.C. Wainwright stated their Neutral rating for the stock in a research note on May 27, 2025, with the firm’s price target at $2. Mizuho coverage for the Unity Biotechnology Inc (UBX) stock in a research note released on May 16, 2025 offered a Neutral rating with a price target of $1. Rodman & Renshaw was of a view on August 22, 2024 that the stock is Buy, while Wedbush gave the stock Outperform rating on November 16, 2023, issuing a price target of $2- $4. ROTH Capital on their part issued Buy rating on January 04, 2022.
